Here's what 'SPOOKED' the market this week...

Key Concepts

• PPI (Producer Price Index): A measure of wholesale inflation, tracking changes in the prices companies pay for inputs.
• Non-GAAP Earnings: Earnings calculated using methods that deviate from Generally Accepted Accounting Principles, often adding back stock-based compensation.
• GLP-1 Drugs: A class of medications originally for diabetes, now widely used for weight loss (e.g., Wegovy by Novo Nordisk, Zepbound by Eli Lilly).
• Rate Cuts: Reductions in interest rates by the Federal Reserve, intended to stimulate economic activity.
• Mag Seven: Refers to the seven largest US technology companies (Apple, Microsoft, Alphabet, Amazon, Nvidia, Tesla, and Meta).
• Stock-Based Compensation: Paying employees with company stock, a common practice in the tech industry.

Market Concerns & Inflationary Pressures

The discussion began with a generally negative outlook for the market this week, driven by several factors. A key concern was the January Producer Price Index (PPI) report, which showed a 0.5% increase – higher than expected. The PPI, a forward-looking indicator of wholesale inflation, measures the prices companies pay for raw materials and inputs. While 0.5% may not seem substantial, the panelists noted it represents a continuation of several months of hotter-than-anticipated inflation reports, raising concerns about long-term inflationary trends. This data is impacting expectations for Federal Reserve policy, pushing back the timeline for anticipated rate cuts. The expectation that incoming Fed Chair Kevin Warsh would initiate rate cuts is now facing challenges, as he would need to convince a potentially hawkish panel.

Economic Data & Upcoming Reports

Upcoming economic data is expected to provide further clarity. The jobs report for February is anticipated to be less robust than January’s significant gain of 365,000 payrolls. Estimates currently project around 650,000 payrolls, with the unemployment rate remaining around 4.3%. Additionally, retail earnings reports from Costco, Target, and other major retailers will be closely watched as indicators of consumer spending.

AI Concerns & Software Valuations

A major topic of discussion was the growing “AI scare” in the markets, particularly impacting software companies. While some companies, like Salesforce, reported favorable earnings (up 6-7%), others, such as Scaler and Snowflake, saw their stock prices decline after earnings releases. This highlights the market’s sensitivity to potential disruption caused by AI. Andrew Berry emphasized concerns about the accounting practices of software companies, specifically their use of Non-GAAP earnings. He argued that these Non-GAAP numbers, which add back stock-based compensation, significantly overstate profitability. Notably, NVIDIA has recently stopped using Non-GAAP numbers. Megan noted a counterpoint, suggesting that attributing stock performance solely to AI concerns risks overlooking broader market rotations, like the recent surge in Caterpillar stock.

GLP-1 Drug Market & Eli Lilly’s Advantage

The GLP-1 drug market, focused on weight loss medications, is currently a two-horse race between Eli Lilly (Zepbound) and Novo Nordisk (Wegovy). Recent trial data revealed Eli Lilly’s Zepbound demonstrated superior results, with patients losing 25.5% of their body weight over 52 weeks, compared to Novo Nordisk’s Wegovy at 23%. This led to a decline in Novo Nordisk’s stock price and a boost for Eli Lilly. However, the panelists also acknowledged that pricing pressures and increased competition from companies like Roche are factors influencing the market. The rapid growth of this segment of the healthcare market is creating uncertainty about future developments.

Technical Terms Explained

• Hawkish Panel: Refers to members of the Federal Reserve’s Federal Open Market Committee (FOMC) who favor tighter monetary policy (e.g., higher interest rates) to control inflation.
• Rotation: A shift in investment capital from one sector or asset class to another, often driven by changing economic conditions or investor sentiment.
• Stock-Based Compensation: A form of employee compensation that involves granting shares of company stock or stock options.
• Catalyst: An event or factor that triggers a significant change in a stock's price or market trend.

Logical Connections & Data Points

The discussion flowed logically from broad market concerns (inflation, interest rates) to specific sector impacts (software, healthcare). The PPI data served as a catalyst for discussing the potential for delayed rate cuts. The AI conversation was linked to concerns about software company valuations and accounting practices. The GLP-1 drug discussion highlighted a rapidly evolving market with significant competitive dynamics.

Specific data points included:

• PPI Increase: 0.5% in January
• Expected February Payrolls: Around 650,000
• Unemployment Rate: Around 4.3%
• Zepbound Weight Loss: 25.5% of body weight over 52 weeks
• Wegovy Weight Loss: 23% of body weight over 52 weeks
• Salesforce Earnings Increase: 6-7%
• Software Stock Decline (from high): Down 20-30%

Synthesis & Main Takeaways

The overarching takeaway is that the market faces a complex and uncertain environment. Inflationary pressures, particularly as indicated by the PPI, are persisting and potentially delaying anticipated rate cuts. The AI narrative is creating volatility in the tech sector, particularly among software companies, and raising questions about valuation methodologies. The GLP-1 drug market is experiencing rapid growth and intense competition. Investors should be cautious, closely monitor upcoming economic data (jobs report, retail earnings), and critically evaluate company financials, particularly in the software sector. Andrew Berry’s point about being wary of Non-GAAP earnings and the market’s tendency to overreact to catalysts like AI are particularly salient. The panelists’ discussion underscores the importance of a nuanced and data-driven approach to investment decision-making.